Role of Flex-Dose Delivery Program in Patients Affected by HCC: Advantages in Management of Tare in Our Experience.

Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101606588 Publication Model: Electronic Cited Medium: Print ISSN: 2077-0383 (Print) Linking ISSN: 20770383 NLM ISO Abbreviation: J Clin Med Subsets: PubMed not MEDLINE

Original Publication: Basel, Switzerland : MDPI AG, [2012]-

Background : Introduced in the latest BCLC 2022, endovascular trans-arterial radioembolization (TARE) has an important role in the treatment of unresectable hepatocellular carcinoma (HCC) as a "bridge" or "downstaging" of disease. The evolution of TARE technology allows a more flexible and personalized target treatment, based on the anatomy and vascular characteristics of each HCC. The flex-dose delivery program is part of this perspective, which allows us to adjust the dose and its radio-embolizing power in relation to the size and type of cancer and to split the therapeutic dose of Y90 in different injections (split-bolus). Methods : From January 2020 to January 2022, we enrolled 19 patients affected by unresectable HCC and candidates for TARE treatment. Thirteen patients completed the treatment following the flex-dose delivery program. Response to treatment was assessed using the mRECIST criteria with CT performed 6 and 9 months after treatment. Two patients did not complete the radiological follow-up and were not included in this retrospective study. The final cohort of this study counts eleven patients. Results : According to mRECIST criteria, six months of follow-up were reported: five cases of complete response (CR, 45.4% of cases), four cases of partial response (PR, 36.4%), and two cases of progression disease (PD, 18.2%). Nine months follow-up reported five cases of complete response (CR, 45.4%), two cases of partial response (PR, 18.2%), and four cases of progression disease (PD, 36.4%). No intra and post-operative complications were described. The average absorbed doses to the hepatic lesion and to the healthy liver tissue were 319 Gy (range 133-447 Gy) and 9.5 Gy (range 2-19 Gy), respectively. Conclusions : The flex-dose delivery program represents a therapeutic protocol capable of "saving" portions of healthy liver parenchyma by designing a "custom-made" treatment for the patient.

Radiol Case Rep. 2019 Mar 23;14(6):662-672. (PMID: 30956745)
World J Gastroenterol. 2019 Aug 28;25(32):4614-4628. (PMID: 31528090)
Phys Med Biol. 2008 Apr 21;53(8):N137-48. (PMID: 18379022)
Q J Nucl Med Mol Imaging. 2011 Apr;55(2):168-97. (PMID: 21386789)
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1570-1584. (PMID: 33433699)
Curr Gastroenterol Rep. 2019 Apr 11;21(4):17. (PMID: 30976932)
EJNMMI Phys. 2020 Dec 14;7(1):75. (PMID: 33315160)
Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2426-2436. (PMID: 33443618)
J Nucl Med. 2010 Sep;51(9):1377-85. (PMID: 20720056)
J Hepatol. 2022 May;76(5):1237-1239. (PMID: 34990748)
Nucl Med Commun. 2012 Jun;33(6):633-40. (PMID: 22407156)
Gut Liver. 2020 Nov 15;14(6):765-774. (PMID: 32050313)
Front Oncol. 2014 Aug 19;4:210. (PMID: 25191640)
Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1682-1699. (PMID: 35146577)
J Immunother Cancer. 2020 Nov;8(2):. (PMID: 33219090)
Hepatology. 2015 Aug;62(2):440-51. (PMID: 25678263)
J Nucl Med. 2006 Jul;47(7):1209-11. (PMID: 16818957)
J Hepatol. 2022 Mar;76(3):681-693. (PMID: 34801630)
Curr Treat Options Oncol. 2020 Mar 19;21(4):31. (PMID: 32193784)
Eur J Cancer. 2021 Sep;154:46-56. (PMID: 34243077)
J Hepatol. 2020 Feb;72(2):288-306. (PMID: 31954493)
EJNMMI Phys. 2021 Nov 12;8(1):77. (PMID: 34767102)
J Nucl Med. 2013 Dec;54(12):2093-100. (PMID: 24136931)
Phys Med. 2020 Dec;80:317-326. (PMID: 33248338)

Keywords: BCLC; HCC; SIRT; TARE; flex-dose; target-therapy

Date Created: 20240427 Latest Revision: 20240429

20250114

PMC11051074

10.3390/jcm13082188

38673461